Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 2:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,124 matching trials from the live ClinicalTrials.gov search.
Conditions
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Interventions
Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more
Conditions
Solid Tumors
Interventions
ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Solid Tumor, Lymphoma
Interventions
MK-2118 (IT), MK-2118 (SC), Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 4 more
Conditions
Advanced Solid Tumors or Lymphomas
Interventions
CA-170
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Conditions
Patients With Advanced Solid Tumors
Interventions
Treatment with ICVB-1042 administered intravenously
Drug
Lead sponsor
IconOVir Bio
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
San Marcos, California • Detroit, Michigan • New York, New York + 7 more
Conditions
Solid Tumors
Interventions
XmAb24306, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 3 more
Conditions
Advanced Solid Tumor
Interventions
RP3, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas
Conditions
Solid Tumors, Non Small Cell Lung Carcinoma
Interventions
EC1456 and EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 12 more
Conditions
Solid Tumor, Adult
Interventions
HL-085
Drug
Lead sponsor
Shanghai Kechow Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
indocyanine green, lidocaine, vinorelbine ditartrate, high performance liquid chromatography, intracellular fluorescence polarization analysis, liquid chromatography, mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms
Interventions
[177Lu]-NeoB, [68Ga]-NeoB, LCZ696
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Baltimore, Maryland + 3 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, doxorubicin hydrochloride
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sphingosine kinase-2 inhibitor ABC294640
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Solid Tumors
Interventions
BMS-986156, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Tucson, Arizona • New Haven, Connecticut
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
MEDI7247
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Huntersville, North Carolina • Nashville, Tennessee
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 25 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Ixabepilone, Sunitinib
Drug
Lead sponsor
Jaime Merchan
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
Interventions
SY-1365 (Part 1), Carboplatin, Fulvestrant, SY-1365 (Cohort 2), SY-1365 (Cohort 5), SY-1365 (Part 2 Single Agent)
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more
Conditions
Locally Advanced Solid Tumor
Interventions
TNG908
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more